Leber Congenital Amaurosis
📧 Sign up to get email alerts when something new happens for Leber Congenital Amaurosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-08-05Clinical Trial Update: Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations [Phase 1]
Phase I trial update of an AAV2-based gene therapy delivering RPE65 for Leber congenital amaurosis due to RPE65 mutations; the study remains…
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 [Phase 1, Phase 2]
A Phase 1/2 follow-on study of the AAV2-hRPE65v2 gene therapy vector for Leber congenital amaurosis (LCA2) is ongoing. The sponsor Spark The…
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating subretinal ATSN-101 for Leber congenital amaurosis caused by biallelic GUCY2D mutations is currently a…
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: Extension Study to Study PQ-110-001 (NCT03140969) [Phase 1, Phase 2]
An extension study update for PQ-110-001 in Leber congenital amaurosis; the study (NCT03140969) has been terminated with results posted on 2…
-
CLINICAL_TRIALS trial_result · 2022-12-27Clinical Trial Update: Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene [Phase 1, Phase 2]
The document reports the completion of a Phase 1/2 clinical trial evaluating QR-110 for Leber congenital amaurosis due to CEP290 mutation, w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) [Phase 1, Phase 2]
Clinical trial update for a gene therapy aimed at treating Leber Congenital Amaurosis (LCA) across Phase 1/2, with completion and results po…
-
CLINICAL_TRIALS trial_result · 2018-04-10Clinical Trial Update: Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations [Phase 1]
A Phase 1 clinical trial update for a gene therapy targeting Leber Congenital Amaurosis caused by RPE65 mutations; the study status is compl…
-
CLINICAL_TRIALS trial_result · 2018-03-26Clinical Trial Update: Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis [Phase 3]
A Phase 3 study evaluating safety and efficacy in subjects with Leber congenital amaurosis due to RPE65 mutations has posted results.
-
CLINICAL_TRIALS trial_result · 2016-11-21Clinical Trial Update: Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families.
The completed clinical trial reports genetic analysis identifying variants associated with Leber Congenital Amaurosis in a large cohort of i…
-
CLINICAL_TRIALS trial_result · 2016-04-29Clinical Trial Update: Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT
A natural history study in inherited retinal diseases caused by mutations in RPE65 or LRAT has completed.
-
CLINICAL_TRIALS trial_result · 2016-04-08Clinical Trial Update: Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis [Phase 1, Phase 2]
Phase 1/2 study of an AAV-RPE65 gene therapy for Leber congenital amaurosis completed, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2015-12-07Clinical Trial Update: Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis [Phase 1, Phase 2]
Phase 1/2 safety study of RPE65 gene therapy for Leber congenital amaurosis has completed, according to the trial update.
-
CLINICAL_TRIALS trial_result · 2014-07-28Clinical Trial Update: Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01) [Phase 1]
Phase 1 extension study update on repeated treatments with QLT091001 in people with Leber congenital amaurosis or retinitis pigmentosa; the …
-
CLINICAL_TRIALS trial_result · 2013-05-14Clinical Trial Update: Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations [Phase 1]
A Phase 1 safety and proof-of-concept trial evaluating oral QLT091001 in individuals with Leber congenital amaurosis or retinitis pigmentosa…